euro adhoc: Intercell AG / Financial Figures/Balance Sheet / Intercell announces preliminary Q4 and full-year 2008 results (E)

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

02.03.2009

» Increased profitability and strong financial position for full-year 2008
» Excellent progress in late-stage pipeline products
» Vaccine to prevent Japanese Encephalitis approved in Australia

Vienna (Austria), March 2, 2009 - Today, the biotech-vaccine company Intercell
AG (VSE: ICLL) announced its preliminary financial results for the fourth
quarter and the full financial year 2008, and presented an update on the
Company's development programs.

Driven by strong revenues of EUR 30.5 m in the fourth quarter and income tax
effects, Intercell´s profit for the full year 2008 was EUR 17.2 m, compared to
EUR 5.0 m in the prior year. The annual revenues increased from EUR 53.3 m in
the year ended December 31, 2007 to EUR 55.8 m in the year ended December 31,
2008. R&D costs for the full year 2008 increased to EUR 56.1 m and enabled the
strong progression of Intercell's late-stage pipeline, including the advanced
clinical programs acquired with Iomai Corporation. Cash and marketable
securities of EUR 190.9 m at year-end give Intercell a strong financial position
and will allow aggressive investment in late-stage pipeline products.

Intercell's vaccine to prevent Japanese Encephalitis, IXIARO®, received positive
CHMP opinion in Europe and product approval in Australia, with U.S. approval
expected in the near future. No additional requests or comments from the
authorities are pending; hence the remaining administrative steps are expected
to be concluded soon. "We have successfully managed to market our first vaccine
and therefore reached one of the most important milestones in the Company's
history - Intercell has proven its ability to develop and produce a product for
global markets. With this achievement, we are looking forward to initiating a
new growth phase for our company," said Intercell Chief Executive Officer Gerd
Zettlmeissl.

DEVELOPMENT PROGRAMS AND PRODUCT PIPELINE

Aggressive investment in four late-stage pipeline products with clinical
efficacy results expected within the next 12 months for Travelers Diarrhea
vaccine patch, Staphylococcus aureus (S. aureus) vaccine candidate, and
Pseudomonas vaccine candidate and Pandemic Influenza

» Traveler's Diarrhea patch vaccine - Recruitment of pivotal Phase III has
begun and initiation of Phase III clinical trial planned for traveling
season in H1 2009

» S. aureus vaccine - Merck & Co., Inc. has advanced the clinical efficacy
trial in cardiothoracic surgery patients and efficacy data is expected mid
2009. The program was expanded with an additional Phase II study in
hemodialysis patients with late-stage kidney disease

» Pseudomonas aeruginosa vaccine - Phase II clinical trial in mechanically
ventilated intensive care patients has been initiated- First efficacy data
is expected H2 2009

» Pandemic Influenza Vaccine Enhancement Patch - Program has been granted
additional funding of USD 12.5 m by U.S. Department of Health and Human
Services (HHS) - Start of Phase II is planned for H1 2009

» Streptococcus pneumoniae vaccine - Phase I clinical trial start with vaccine
candidate to prevent infections with the bacterium Streptococcus pneumoniae
is planned for March 2009

» herapeutic Hepatitis C vaccine - Initiation of next clinical trials will take
advantage of a combination treatment and the use of IC31® as more potent
adjuvant - strategic partnering process ongoing

» Tuberculosis vaccine - Phase I/II clinical development program of Statens
Serum Institut (SSI), Intercell and Sanofi Pasteur is proceeding according
to plan

» Group B Streptococcus vaccine - program has been licensed to Novartis

KEY FINANCIAL INFORMATION

in EUR thousands
Year ended December 31,
2008 2007 2006

Revenues 55,763 53,349 23,452

Net profit/(loss) 17,175 5,009 (16,143)

Net operating cash flow (10,186) 41,686 (7,979)

Cash and marketable
securities, end of the
year 190,865 287,571 94,421

For the full report please visit www.intercell.com

Further inquiry note:
Intercell AG
Lucia Malfent
Head of Communications
Tel. +43 1 20620-303
[email protected]

end of announcement euro adhoc
--------------------------------------------------------------------------------

emitter: Intercell AG
Campus Vienna Biocenter 3
A-1030 Wien
phone: +43 1 20620-0
FAX: +43 1 20620-800
mail: [email protected]
WWW: www.intercell.com
sector: Biotechnology
ISIN: AT0000612601
indexes: ATX Prime, ATX
stockmarkets: official market: Wiener Börse AG
language: English

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | OTB

print